Today’s episodes show why immediate threats, molecular data, and trial endpoints should shape treatment before momentum takes over.
Before starting systemic therapy for metastatic colorectal cancer with the primary still in situ, exclude obstruction, bleeding, or perforation and get molecular profiling early, because both safety and first-line choice depend on it.
Today’s briefing ties together two themes: biomarker-led sequencing in metastatic colorectal cancer and disciplined interpretation of neutral evidence in HSV encephalitis. In the colorectal episode, the practical priorities are to check whether an intact primary is threatening obstruction, bleeding, or perforation before chemotherapy, send MSI/MMR and broader sequencing early, and use liver-directed imaging before declaring disease unresectable.
The neurology episode makes the same broader point from a different angle. A phase III trial found no clear 26-week benefit from adjunct dexamethasone in CSF-confirmed HSV encephalitis despite similar safety outcomes, so neutral safety data should not be mistaken for efficacy. Together, these episodes reward the same habit: define the subgroup properly, then sequence treatment with intent.
The most important early decision in metastatic colorectal cancer is whether the primary tumour can safely stay in situ while systemic therapy begins. Exclude obstruction, bleeding, or perforation, get MSI/MMR and broader sequencing early, and use liver-directed imaging before dismissing resection or ablation.
Adjunct dexamethasone should not be assumed to improve confirmed HSV encephalitis simply because it appears safe. In this phase III trial, 26-week outcomes, mortality, and discharge timing were similar to acyclovir alone, and the findings should not be extrapolated to undifferentiated encephalitis.
.svg)